Pulmonary Alveolar Proteinosis Clinical Trial
Official title:
Study of Subcutaneous Injection of Low-dose Recombinant Granulocyte Macrophage-Colony Stimulating Factor (rhGM-CSF) +/- Whole Lung Lavage(WLL) in Pulmonary Alveolar Proteinosis.
The purpose of this study is to establish an efficient and economic treatment scheme by evaluation of the safety and efficacy of subcutaneous injection of low-dose rhGM-CSF, or of similar injection after whole lung lavage , in patients with PAP.
The purpose of this study is to establish an efficient and economic treatment scheme by evaluation of the safety and efficacy of subcutaneous injection of low-dose rhGM-CSF, or of similar injection after whole lung lavage , in patients with PAP. During the observation, study visits will occur at the end of each month. During the 1-year follow-up period which is lasting 6 months after the treatment, all participants will be required to check the various efficacy indicators. ;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00030056 -
GM-CSF in Patients With Pulmonary Alveolar Proteinosis
|
Phase 2 | |
Completed |
NCT03887169 -
Administration of Methionine in Patients With Pulmonary Alveolar Proteinosis by Mutation of the MARS Gene.
|
Phase 1/Phase 2 | |
Completed |
NCT02468908 -
Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects
|
Phase 1 | |
Enrolling by invitation |
NCT04326036 -
Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection
|
Early Phase 1 | |
Completed |
NCT03007134 -
Multicenter International Cross-Sectional Evaluation of Pulmonary Alveolar Proteinosis Trial
|
N/A | |
Completed |
NCT00552461 -
Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis
|
Phase 2 | |
Completed |
NCT04516577 -
Updated Severity and Prognosis Score of Pulmonary Alveolar Proteinosis
|
||
Recruiting |
NCT02852928 -
European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank
|
||
Completed |
NCT02081092 -
Evaluation and Treatment Planning of Patients With PAP Using Thrive Ultra Short Echo Time MRI and CT
|
||
Recruiting |
NCT03316651 -
Sequential Therapy With WLL/Inhaling GM-CSF for Autoimmune Pulmonary Alveolar Proteinosis
|
Phase 2 | |
Enrolling by invitation |
NCT05300360 -
Prevalence of Adenosine Deaminase (ADA) Enzyme Deficiency Disease in Adult Patients With Pulmonary Alveolar Proteinosis
|
||
Recruiting |
NCT02461615 -
A National Registry For Pulmonary Alveolar Proteinosis
|